Compound Ir5 (Antitumor agent-145) serves as a tumor inhibitor characterized by significant fluorescence and mitochondrial targeting. It promotes anti-cancer activity by inducing necroptosis and stimulating the necroptosis-related immune response [1].

Antitumor agent-145 (Compound Ir5) has an IC 50 value of 0.49 μM against BEL-7402/DDP cells over 48 hours with a resistance factor (RF) of 1.04, and it exhibits no significant cytotoxicity [1].

Antitumor agent-145 (Compound Ir5), administered intravenously at doses of 1.5 or 3.0 mg/kg every other day for 21 days, effectively reduces tumor volume in BALB/c mice without causing significant liver or kidney dysfunction [1]. In the BEL-7402/DDP tumor xenograft model, Ir5 significantly inhibits the growth and metastasis of CDDP-resistant tumors, displaying an inhibition rate of tumor growth (IRT) of 40.0% at 1.5 mg/kg and 58.1% at 3 mg/kg, compared to 10.1% in the CDDP group, without inducing notable tissue damage [1].